Data Set Name: aeclin.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | CAE_1020 | Num | 8 | | Description of adverse event |
| 5 | CAE_1030 | Char | 6 | | ICD9 Code |
| 6 | CAE_1040 | Num | 8 | | Date started (number of days since enrollment date) |
| 7 | CAE_1050 | Num | 8 | | Date stopped (number of days since enrollment date) |
| 8 | CAE_1060 | Num | 8 | YESF. | Flag: Ongoing at current visit? |
| 9 | CAE_1070 | Num | 8 | | Duration in hours if < 24 hours |
| 10 | CAE_1080 | Num | 8 | CAE_1080F. | Event type (intermittent or continuous) |
| 11 | CAE_1090 | Num | 8 | CAE_1090F. | Event severity |
| 12 | CAE_1100 | Num | 8 | YNF. | Serious Adverse Event? |
| 13 | CAE_1110 | Num | 8 | CAE_1110F. | Likelihood of relationship to study drug |
| 14 | CAE_1120 | Num | 8 | CAE_1120F. | Change in study medications |
| 15 | CAE_1130 | Num | 8 | CAE_1130F. | Event outcome |
| 16 | CAE_1140 | Num | 8 | CAE_1140F. | Treatment required |

Data Set Name: aelab.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | LAE_1000 | Num | 8 | | Test date (number of days since enrollment date) |
| 5 | LAE_1010 | Num | 8 | LAE_1010F. | Laboratory test |
| 6 | LAE_1020 | Num | 8 | LAE_1020F. | Abnormality observed |
| 7 | LAE_1030 | Num | 8 | YNF. | Was this Laboratory Adverse Event considered serious? |
| 8 | LAE_1040 | Num | 8 | LAE_1040F. | Likelihood of relationship to study drug |
| 9 | LAE_1050 | Num | 8 | YNF. | Did the subject require treatment with medication other than study drugs for this Laboratory Adverse Event? |
| 10 | LAE_1060 | Num | 8 | YNF. | Did the subject require any other type of treatment for this Laboratory Adverse Event? |
| 11 | LAE_1070 | Num | 8 | LAE_1070F. | Adverse Event status |
| 12 | LAE_1080 | Num | 8 | | Date Adverse Event resolved (number of days since enrollment date) |

Data Set Name: ast_hx.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | AHX_1000 | Num | 8 | AHX_1000F. | 1. What is your relationship to the child? |
| 5 | AHX_1010 | Num | 8 | | 2. How old was the child when chest symptoms suggesting asthma first began? (years) |
| 6 | AHX_1020 | Num | 8 | | 2. How old was the child when chest symptoms suggesting asthma first began? (months) |
| 7 | AHX_1030 | Num | 8 | | 3. How old was the child when a doctor first said he or she had asthma? (years) |
| 8 | AHX_1040 | Num | 8 | | 3. How old was the child when a doctor first said he or she had asthma? (months) |
| 9 | AHX_1050 | Num | 8 | YNF. | 4. Has the child ever been hospitalized overnight for asthma? |
| 10 | AHX_1060 | Num | 8 | | 4a. If YES, during the past 12 months, how many times has the child been hospitalized overnight for asthma? |
| 11 | AHX_1070 | Num | 8 | YNF. | 5. Has the child ever been admitted to an intensive care unit for asthma? |
| 12 | AHX_1080 | Num | 8 | | 5a. If YES, during the past 12 months, how many times has the child been admitted to an intensive care unit for asthma? |
| 13 | AHX_1090 | Num | 8 | | 6a. During the past 12 months, how many times has the child been seen in an emergency department for asthma? |
| 14 | AHX_1100 | Num | 8 | | 6b. During the past 12 months, how many times has the child been seen at a doctor's office for asthma? (Include both routine visits and visits for acute problems) |
| 15 | AHX_1110 | Num | 8 | | 6c. During the past 12 months, how many days of work or school did the child miss because of asthma? |
| 16 | AHX_1120 | Num | 8 | | 6d. During the past 12 months, how many days of work did you miss because of the child's asthma? |
| 17 | AHX_1130 | Num | 8 | AHX_1130TO1250F. | 7. Is the child's asthma provoked on exposure to house dust? |
| 18 | AHX_1140 | Num | 8 | AHX_1130TO1250F. | 8. Is the child's asthma provoked on exposure to animals? |
| 19 | AHX_1150 | Num | 8 | AHX_1130TO1250F. | 9. Is the child's asthma provoked by emotional factors? (e.g., stress) |
| 20 | AHX_1160 | Num | 8 | AHX_1130TO1250F. | 10. Is the child's asthma provoked by exercise/play? |
| 21 | AHX_1170 | Num | 8 | AHX_1130TO1250F. | 11. Is the child's asthma provoked on exposure to damp, musty area? (e.g., damp basement) |
| 22 | AHX_1180 | Num | 8 | AHX_1130TO1250F. | 12. Is the child's asthma provoked on exposure to tobacco smoke? |
| 23 | AHX_1190 | Num | 8 | AHX_1130TO1250F. | 13. Is the child's asthma provoked on exposure to a change in the weather? |
| 24 | AHX_1200 | Num | 8 | AHX_1130TO1250F. | 14. Is the child's asthma provoked on respiratory infections? |
| 25 | AHX_1210 | Num | 8 | AHX_1130TO1250F. | 15. Is the child's asthma provoked on exposure to chemicals? (e.g., perfume, household cleaners) |
| 26 | AHX_1220 | Num | 8 | AHX_1130TO1250F. | 16. Is the child's asthma provoked by food? |
| 27 | AHX_1230 | Num | 8 | AHX_1130TO1250F. | 17. Is the child's asthma provoked on exposure to cold air? |
| 28 | AHX_1240 | Num | 8 | AHX_1130TO1250F. | 18. Is the child's asthma provoked by aspirin? |
| 29 | AHX_1250 | Num | 8 | AHX_1130TO1250F. | 19. Is the child's asthma provoked on exposure to spring and fall pollens? |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------------|--|
| 30 | AHX_1260 | Num | 8 | YNF. | 20. Has the child ever had hay fever? |
| 31 | AHX_1270 | Num | 8 | | 20a. At what age did the child FIRST have hay fever? (years) |
| 32 | AHX_1280 | Num | 8 | | 20a. At what age did the child FIRST have hay fever? (months) |
| 33 | AHX_1290 | Num | 8 | YNF. | 20b. During the past 12 months, did the child have hay fever? |
| 34 | AHX_1300 | Num | 8 | YNF. | 20c. Has the child ever seen a doctor or other health practitioner because of hay fever? |
| 35 | AHX_1310 | Num | 8 | YNF. | 21. Has the child ever had atopic dermatitis (eczema)? |
| 36 | AHX_1320 | Num | 8 | | 21a. At what age did the child FIRST have atopic dermatitis (eczema)? (years) |
| 37 | AHX_1330 | Num | 8 | | 21a. At what age did the child FIRST have atopic dermatitis (eczema)? (months) |
| 38 | AHX_1340 | Num | 8 | YNF. | 21b. During the past 12 months, did the child have atopic dermatitis? |
| 39 | AHX_1350 | Num | 8 | YNF. | 21c. Has the child ever seen a doctor or other health practitioner because of atopic dermatitis? |
| 40 | AHX_1360 | Num | 8 | YNF. | 22. Has a doctor or other health practitioner ever said that the child has allergies? |
| 41 | AHX_1370 | Num | 8 | YNF. | 23a. To which of the following did a doctor or other health practitioner say the child was allergic: Medicines |
| 42 | AHX_1380 | Num | 8 | YNF. | 23b. To which of the following did a doctor or other health practitioner say the child was allergic: Foods |
| 43 | AHX_1390 | Num | 8 | YNF. | 23c. To which of the following did a doctor or other health practitioner say the child was allergic: Things you breathe in or inhale (e.g., dust, pollens, molds, animal fur, or dander) |
| 44 | AHX_1400 | Num | 8 | YNF. | 23d. To which of the following did a doctor or other health practitioner say the child was allergic: Stinging insects such as bees or wasps |
| 45 | AHX_1410 | Num | 8 | YNF. | 23e. To which of the following did a doctor or other health practitioner say the child was allergic: Other |
| 46 | AHX_1420 | Num | 8 | AHX_1420F. | 24. On average, during the past MONTH, how often has the child had a cough, wheeze, shortness of breath, or chest tightness? |
| 47 | AHX_1430 | Num | 8 | AHX_1430TO1450F. | 25. On average, during the past MONTH, how often was the child awakened from sleep because of coughing, wheezing, shortness of breath, or chest tightness? |
| 48 | AHX_1440 | Num | 8 | AHX_1430TO1450F. | 26. On average, during the past MONTH, how often has the child had cough, wheeze, shortness of breath, or chest tightness while exercising or playing? |
| 49 | AHX_1450 | Num | 8 | AHX_1430TO1450F. | 27. On average, during the past MONTH, how often does asthma keep the child from doing what the child wants? |
| 50 | AHX_1460 | Num | 8 | AHX_1460F. | 28. In general, during the past MONTH, how bothered was the child by his/her asthma? |

Data Set Name: cap_feia.sas7bdat

| Num | Variable | Type | Len | Label |
|-----|----------|------|-----|---|
| 1 | SUBJ_ID | Num | 8 | Public Subject ID |
| 2 | VNUM | Num | 8 | Visit Number |
| 3 | VDATE | Num | 8 | Visit Date (number of days since enrollment date) |
| 4 | CAP_1000 | Num | 8 | 1. Mite Mix CAP/FEIA test results (Au/L) |
| 5 | CAP_1010 | Num | 8 | 2. Roach Mix CAP/FEIA test results (Au/L) |
| 6 | CAP_1020 | Num | 8 | 3. Cat CAP/FEIA test results (Au/L) |
| 7 | CAP_1030 | Num | 8 | 4. Dog CAP/FEIA test results (Au/L) |
| 8 | CAP_1040 | Num | 8 | 5. Mold Mix CAP/FEIA test results (Au/L) |
| 9 | CAP_1050 | Num | 8 | 6. Grass Mix CAP/FEIA test results (Au/L) |
| 10 | CAP_1060 | Num | 8 | 7. Tree Mix CAP/FEIA test results (Au/L) |
| 11 | CAP_1070 | Num | 8 | 8. Weed Mix CAP/FEIA test results (Au/L) |
| 12 | CAP_1080 | Num | 8 | 9. Milk CAP/FEIA test results (Au/L) |
| 13 | CAP_1090 | Num | 8 | 10. Egg CAP/FEIA test results (Au/L) |
| 14 | CAP_1100 | Num | 8 | 11. Peanut CAP/FEIA test results (Au/L) |
| 15 | CAP_1110 | Num | 8 | 12. OtherCAP/FEIA test results (Au/L) |
| 16 | CAP_1120 | Num | 8 | 13. OtherCAP/FEIA test results (Au/L) |

Data Set Name: cmed_as.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | CMD_1010 | Num | 8 | | Name of Medication |
| 5 | CMD_1000 | Char | 4 | | Med Code |
| 6 | CMD_1040 | Num | 8 | | Frequency |
| 7 | CMD_1060 | Num | 8 | | Med Start Date (number of days since enrollment date) |
| 8 | CMD_1090 | Num | 8 | | Med Stop Date (number of days since enrollment date) |
| 9 | CMD_1100 | Num | 8 | YESF. | Flag: Ongoing at Data Entry |

Data Set Name: comply.sas7bdat

| Num | Variable | Type | Len | Label |
|-----|----------|------|-----|---|
| 1 | SUBJ_ID | Num | 8 | Public Subject ID |
| 2 | VNUM | Num | 8 | Visit Number |
| 3 | VDATE | Num | 8 | Visit Date (number of days since enrollment date) |
| 4 | CMP_1120 | Num | 8 | 1a. Number of tablets dispensed in eDEM vial |
| 5 | CMP_1130 | Num | 8 | 1b. Number of tablets returned in eDEM vial |
| 6 | CMP_1140 | Num | 8 | 1c. Number of presecribed doses |
| 7 | CMP_1150 | Num | 8 | 1d. Actual number of tables taken (Question #1a - Question #1b) |
| 8 | CMP_1160 | Num | 8 | 1e. Percent compliance = (Question #1d / Question #1c) x 100 |
| 9 | CMP_1000 | Num | 8 | 2a. Number of monitored days |
| 10 | CMP_1010 | Num | 8 | 2b. Number of doses taken |
| 11 | CMP_1020 | Num | 8 | 2c. % Prescribed number of doses taken |
| 12 | CMP_1021 | Num | 8 | 2d. Doses in time window/prescribed doses |
| 13 | CMP_1070 | Num | 8 | 3a. Number of scheduled inhalations since the last visit |
| 14 | CMP_1080 | Num | 8 | 3b. Dose counter number on the first Diskus |
| 15 | CMP_1090 | Num | 8 | 3c. Dose counter number on the second Diskus |
| 16 | CMP_1100 | Num | 8 | 3d. 120 - Question #3b - Question #3c |
| 17 | CMP_1110 | Num | 8 | 3e. Percent compliance = (Question #3d / Question #3a) x 100 |

Data Set Name: diary.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | DIARYDT | Num | 8 | | Diary Date (number of days since enrollment date) |
| 5 | DRY_1000 | Num | 8 | YNF. | 1. Awakened last night by asthma? |
| 6 | DRY_1010 | Num | 8 | | 2. Time of AM Peak Flow |
| 7 | DRY_1020 | Num | 8 | | 3. AM Peak Flow (liters/min) |
| 8 | DRY_1030 | Num | 8 | | 3. FLAG: Circle the value if you have used your RESCUE inhaler in the last 2 hours. |
| 9 | DRY_1040 | Num | 8 | | 4. Number of AM Study Diskus inhalations taken |
| 10 | DRY_1050 | Num | 8 | | 5. Coordinator Completed: AM FEV1 (liters) |
| 11 | DRY_1060 | Num | 8 | | 6. Time of PM Peak Flow |
| 12 | DRY_1070 | Num | 8 | | 7. PM Peak Flow (liters/min) |
| 13 | DRY_1080 | Num | 8 | | 7. FLAG: Circle the value if you have used your RESCUE inhaler in the last 2 hours. |
| 14 | DRY_1090 | Num | 8 | | 8. Number of PM Study Diskus inhalations taken |
| 15 | DRY_1100 | Num | 8 | | 9. Number of PM Study tablets taken |
| 16 | DRY_1110 | Num | 8 | | 10. Coordinator Completed: PM FEV1 (liters) |
| 17 | DRY_1120 | Num | 8 | SYMRATINGSCALEF. | 11. Asthma Sympotoms: Coughing from asthma |
| 18 | DRY_1130 | Num | 8 | SYMRATINGSCALEF. | 12. Asthma Sympotoms: Wheezing |
| 19 | DRY_1140 | Num | 8 | | 13. Rescue Inhaler: Before or after exercise |
| 20 | DRY_1150 | Num | 8 | | 14. Rescue Inhaler: For asthma symptoms or low peak flow |
| 21 | DRY_1160 | Num | 8 | YNF. | 15. Absent from school or work for asthma? |
| 22 | DRY_1170 | Num | 8 | YNF. | 16. Contacted doctor for asthma? |
| 23 | DRY_1180 | Num | 8 | | 17. FLAG: Parent/Legal Guardian initials |

Data Set Name: drug_seq.sas7bdat

| Num | Variable | Type | Len | Label |
|-----|----------|------|-----|---|
| 1 | SUBJ_ID | Num | 8 | Public Subject ID |
| 2 | DRUG_SEQ | Char | 10 | Treatment sequence assigned to subject at randomization |

Data Set Name: elig1.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | E1_1000 | Num | 8 | YNF. | 1. Has a parent/legal guardian appropriately signed and dated the informed consent? |
| 5 | E1_1010 | Num | 8 | | 2. If YES, date form signed (number of days since enrollment date) |
| 6 | E1_1020 | Num | 8 | YNF. | 3. Has the participant appropriately signed and dated the assent form, or if the participant is less than 7 years old, has the participant given verbal assent? |
| 7 | E1_1030 | Num | 8 | | 4. If YES, record the date verbal assent was given (number of days since enrollment date) |
| 8 | E1_1040 | Num | 8 | YNF. | 5. Is the participant 6 to <18 years old? |
| 9 | E1_1050 | Num | 8 | YNF. | 6. Has the participant smoked 11 or more cigarettes or any other substance in the past year? |
| 10 | E1_1060 | Num | 8 | YNF. | 7. Has the participant used smokeless tomacco products (chew, snuff) 11 or more times in the past year? |
| 11 | E1_1070 | Num | 8 | YNF. | 8. Has the participant ever had chicken pox or received the chicken pox vaccine? |
| 12 | E1_1080 | Num | 8 | YNF. | 9. Does the participant have a chronic or active lung disease other than asthma? |
| 13 | E1_1090 | Num | 8 | YNF. | 10. Does the participant have a significant medical illness other than asthma (e.g. thyroid disease, diabetes mellitus, Cushings's, Addison's, or hepatic disease)? |
| 14 | E1_1100 | Num | 8 | YNF. | 11. Does the participant have a history of cataracts, glaucoma, or other medical disorders (such as thrush that is difficult to treat) associated with an adverse effect to glucocorticoids? |
| 15 | E1_1110 | Num | 8 | YNF. | 12. Does the participant have concurrent medical problems other than asthma that are likely to require oral prednisone during the study? |
| 16 | E1_1120 | Num | 8 | YNF. | 13. During the past year, has the participant had 4 or more corticosteroid bursts for asthma exacerbations? |
| 17 | E1_1130 | Num | 8 | YNF. | 14. During the past year, has the participant been hospitalized 2 or more times for asthma? |
| 18 | E1_1140 | Num | 8 | YNF. | 15. Has the participant ever had an asthma exacerbation resulting in intubation and mechanical ventilation? |
| 19 | E1_1150 | Num | 8 | YNF. | 16. Has the participant ever had a seizure (during and asthma episode) that the physician thought was due to asthma? |
| 20 | E1_1160 | Num | 8 | YNF. | 17. Is the participant receiving allergy shots? |
| 21 | E1_1170 | Num | 8 | YNF. | 17a. If YES, has the dose been changed in the past 3 months? |
| 22 | E1_1180 | Num | 8 | YNF. | 18. Has the participant ever had an adverse reaction to fluticasone proprionate, montelukast, or any of their ingredients? |
| 23 | E1_1190 | Num | 8 | YNF. | 19. Has the participant had a respiratory tract infection within the past 4 weeks? |
| 24 | E1_1200 | Num | 8 | YNF. | 20. Has the participant had a significant exacerbation of asthma within the past 4 weeks? |
| 25 | E1_1210 | Num | 8 | YNF. | 21. During the past 4 weeks, has the participant had a combination of asthma symptoms or bronchodilator use for relief for asthma symptoms or signs on an average of 3 or more days per week? |
| 26 | E1_1220 | Num | 8 | YNF. | 22a. Has the participant received any of the following treatments in the past 4 weeks? Oral inhaled corticosteroid treatment |
| 27 | E1_1230 | Num | 8 | YNF. | 22b. Has the participant received any of the following treatments in the past 4 weeks? Systemic corticosteroid treatment (oral or injectable) |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 28 | E1_1240 | Num | 8 | YNF. | 23. Has the participant used any of the drugs listed on the Exclusionary Drugs reference card (EXCLDRUG) during the designated washout periods? |
| 29 | E1_1250 | Num | 8 | | 24. Is the BMI of the participant > 35 kg/m ² ? |
| 30 | E1_1260 | Num | 8 | YNF. | 24. Has the participant had her first period? |
| 31 | E1_1270 | Num | 8 | YNF. | 24a. Is the participant currently pregnant or nursing? |
| 32 | E1_1280 | Num | 8 | YNF. | 24b. Is the participant currently using an acceptable birth control method? |
| 33 | E1_1290 | Num | 8 | YNF. | 25. Does the participant's family have plans to move out of the area within the next 5 months? |
| 34 | E1_1300 | Num | 8 | YNF. | 26. Is there any other reason for which this participant should not be included in this study? |
| 35 | E1_1310 | Num | 8 | YNF. | 27. Is the participant eligible? |
| 36 | E1_1320 | Num | 8 | | Flag: Physician/CC signature |
| 37 | E1_1330 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) |

Data Set Name: elig2.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | E2_1000 | Num | 8 | YNF. | 1. Is the participant able to perform the required lung function procedures? |
| 5 | E2_1010 | Num | 8 | YNF. | 2. Is the participant able to perform reproducible spirometry? |
| 6 | E2_1020 | Num | 8 | YNF. | 3. Is the participant's pre-bronchodilator FEV1% predicted >= 70%? (Result of best effort) |
| 7 | E2_1030 | Num | 8 | | 4. Is the participant able to demonstrate reversible airflow obstruction (>= 12% improvement in FEV1 following the maximal bronchodilator testing procdure with albuterol MDI)? |
| 8 | E2_1040 | Num | 8 | YNF. | 4. Is the participant eligible? |
| 9 | E2_1050 | Num | 8 | | 5. Personal best PEFR resulting from 3 acceptable blows on the AM1 device. |
| 10 | E2_1060 | Num | 8 | | Flag: Physician/CC signature |
| 11 | E2_1070 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) |

Data Set Name: elig3.sas7bdat

| Num | Variable | Type | Len | Format | Label | |
|-----|----------|------|-----|--------|---|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID | |
| 2 | VNUM | Num | 8 | | Visit Number | |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) | |
| 4 | E3_1000 | Num | 8 | YNF. | 1a. Has the study participant received any of the following treatments since the last study visit? Oral inhaled corticosteroid treatment | |
| 5 | E3_1010 | Num | 8 | YNF. | 1b. Has the study participant received any of the following treatments since the last study visit? Systemic corticosteroid treatment (oral or injectable) | |
| 6 | E3_1020 | Num | 8 | YNF. | 2. Has the participant used any of the drugs listed on the Exclusionary Drugs reference card (EXCLDRUG) during the designated washout periods? | |
| 7 | E3_1030 | Num | 8 | | 3. Number of days since Visit 1, excluding today and the participant's Visit 1 date | |
| 8 | E3_1040 | Num | 8 | | 4a. Diary and peak flow compliance - Number of complete measurements in the defined interval | |
| 9 | E3_1050 | Num | 8 | | 4b. Diary and peak flow compliance - Percent compliance = (Question #4a / Question #3 x 5) x 100 | |
| 10 | E3_1060 | Num | 8 | YNF. | 4c. Diary and peak flow compliance - Is Question #4b >= 80%? | |
| 11 | E3_1070 | Num | 8 | YNF. | 5. Is the participant eligible? | |
| 12 | E3_1080 | Num | 8 | | 6a. Albuterol use - Number of puffs of albuterol used for asthma symptoms or low peak flow (Question #14 on the Diary Card) | |
| 13 | E3_1090 | Num | 8 | | 6b. Albuterol use - Average number of puffs of albuterol per day used for asthma symptoms or low peak flow Average = (Question #6a / Question #3) | |
| 14 | E3_1100 | Num | 8 | YNF. | NF. 6c. Albuterol use - Is Question #6b > 8.0? | |
| 15 | E3_1110 | Num | 8 | | 7a. Night awakenings - Number of days in the defined interval with night awakenings due to asthma symptoms | |
| 16 | E3_1120 | Num | 8 | | 7b. Night awakenings - Average number of days per week with night awakenings due to asthma symptoms Average = (Question $\#7a$ / Question $\#3$) x 7 | |
| 17 | E3_1130 | Num | 8 | YNF. | 7c. Night awakenings - Is Question #7b >= 2.0? | |
| 18 | E3_1140 | Num | 8 | YNF. | 8a. Peak flow variability - Are there any usable peak flow variability measurements for this subject? | |
| 19 | E3_1150 | Num | 8 | | 8b. Peak flow variability - Average peak flow variability (see the Eligiiblity Calculator Report, or use the Peak Flow Variability Worksheet) | |
| 20 | E3_1160 | Num | 8 | YNF. | 8c. Peak flow variability - Is Question #8b >= 30.0%? | |
| 21 | E3_1170 | Num | 8 | YNF. | 9. Are the liver function tests for this participant within acceptable range? | |
| 22 | E3_1171 | Num | 8 | YNF. | 10. Is the participant eligibile? | |
| 23 | E3_1172 | Num | 8 | YNF. | 11. Was the participant able to demonstrate reversible airflow obstruction (>= 12% improvement in FEV1 following the maximal bronchodilator testing procedure at Visit 1 with albuterol MDI)? | |
| 24 | E3_1173 | Num | 8 | YNF. | 12. Is the participant's PC20 <= 12.5 mg/ml? | |
| 25 | E3_1174 | Num | 8 | YNF. | 13. Is the participant eligible? | |
| 26 | E3_1180 | Num | 8 | YNF. | 14. Does the parent/legal guardian believe that the participant and family will be able to comply with the study schedule and study requirements? | |
| 27 | E3_1190 | Num | 8 | YNF. | 15. Is the participant able to coordinate the use of the Diskus? | |
| 28 | E3_1200 | Num | 8 | YNF. | 16. Is the participant able to perform the required lung function procedures? | |
| 29 | E3_1210 | Num | 8 | YNF. | 17. Is there any other reason for which this participant should not be included in this study? | |

| Num | Variable | Type | Len | Format | Label | |
|-----|----------|------|-----|--------|--|--|
| 30 | E3_1220 | Num | 8 | YNF. | 18. Is the participant eligible? | |
| 31 | E3_1260 | Num | 8 | | Flag: Physician/CC signature | |
| 32 | E3_1270 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) | |

Data Set Name: eno.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | ENO_1000 | Num | 8 | YNF. | 1. During the past 24 hours, has the child used sustained-release theophylline? |
| 5 | ENO_1010 | Num | 8 | YNF. | 2. During the past 12 hours, has the child used a long-acting bronchodilator (i.e., salmeterol)? |
| 6 | ENO_1020 | Num | 8 | YNF. | 3. During the past 4 hours, has the child used a short-acting bronchdilator? |
| 7 | ENO_1030 | Num | 8 | YNF. | 4. During the past 2 weeks, has the child had any respiratory infections, colds, or bronchitis? |
| 8 | ENO_1035 | Num | 8 | YNF. | 5. Has the child smoked cigarettes or any other substance in the past month? |
| 9 | ENO_1036 | Num | 8 | YNF. | 5a. If YES, has the child smoked within the past hour? |
| 10 | ENO_1040 | Num | 8 | YNF. | 6. Is there any other reason the child should not proced with the exhaled nitric oxide procedure? |
| 11 | ENO_1045 | Num | 8 | YNF. | 7. Did the child eat or drink in the past hour? |
| 12 | ENO_1050 | Num | 8 | YNF. | 8. Is the child eligibile to proceed with the exhaled nitric oxide procedure? |
| 13 | ENO_1060 | Num | 8 | | 10. ENO Measurement #1 - Time |
| 14 | ENO_1070 | Num | 8 | | 10. ENO Measurement #1 - Measured FENO |
| 15 | ENO_1080 | Num | 8 | | 11. ENO Measurement #2 - Time |
| 16 | ENO_1090 | Num | 8 | | 11. ENO Measurement #2 - Measured FENO |
| 17 | ENO_1100 | Num | 8 | | 12. ENO Measurement #3 - Time |
| 18 | ENO_1110 | Num | 8 | | 12. ENO Measurement #3 - Measured FENO |
| 19 | ENO_1120 | Num | 8 | | 13. Average FENO |
| 20 | ENO_1130 | Num | 8 | | 14. Average VNO |

Data Set Name: heq.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | HEQ_1000 | Num | 8 | RESPONDENTF. | 1. What is your relationship to the child? |
| 5 | HEQ_1010 | Num | 8 | HEQ_1010F. | 2. How long has the child lived in his/her current home? |
| 6 | HEQ_1020 | Num | 8 | YNF. | 3a. Are any of the following located on your property? - Barns |
| 7 | HEQ_1030 | Num | 8 | YNF. | 3b. Are any of the following located on your property? - Hay |
| 8 | HEQ_1040 | Num | 8 | YNF. | 3c. Are any of the following located on your property? - Woodsheds |
| 9 | HEQ_1050 | Num | 8 | YNF. | 3d. Are any of the following located on your property? - Firewood |
| 10 | HEQ_1060 | Num | 8 | YNF. | 3e. Are any of the following located on your property? - Chicken coops |
| 11 | HEQ_1070 | Num | 8 | YNF. | 3f. Are any of the following located on your property? - Horses |
| 12 | HEQ_1080 | Num | 8 | HEQ_1080F. | 4. Which best describes the child's current home? |
| 13 | HEQ_1090 | Num | 8 | | 5. About how old is the child's current home? (years) |
| 14 | HEQ_1100 | Num | 8 | YNF. | 6. Does the child's home use a portable heater? |
| 15 | HEQ_1110 | Num | 8 | YNF. | 7. Does the child's home use a wood burning stove as a primary source of heat? |
| 16 | HEQ_1120 | Num | 8 | YNF. | 8. Does the child's home use a cooling system? |
| 17 | HEQ_1130 | Num | 8 | HEQ_1130F. | 9. Which type of cooling system is used in the child's home? |
| 18 | HEQ_1140 | Num | 8 | YNF. | 10a. Which rooms use a window unit? - Child's bedroom |
| 19 | HEQ_1150 | Num | 8 | YNF. | 10b. Which rooms use a window unit? - Other bedrooms |
| 20 | HEQ_1160 | Num | 8 | YNF. | 10c. Which rooms use a window unit? - Living or family room |
| 21 | HEQ_1170 | Num | 8 | YNF. | 10d. Which rooms use a window unit? - Kitchen |
| 22 | HEQ_1180 | Num | 8 | YNF. | 10e. Which rooms use a window unit? - Other |
| 23 | HEQ_1190 | Num | 8 | YNDKF. | 11. Does the child's home use a humidifier? (Include humidifier built into the heating system of the child's home) |
| 24 | HEQ_1200 | Num | 8 | YNDKF. | 12. Does the child's home use a de-humidifier? (Include de-humidifier built into the cooling system of the child's home) |
| 25 | HEQ_1210 | Num | 8 | YNDKF. | 13. Has there been water damage to the child's home, basement, or its contents during the past 12 months? |
| 26 | HEQ_1220 | Num | 8 | YNDKF. | 14. Has there been any mold or mildew, on any surfaces, inside the child's home in the past 12 months? |
| 27 | HEQ_1230 | Num | 8 | YNF. | 15a. Which room(s) have or have had mold or mildew? - Bathroom(s) |
| 28 | HEQ_1240 | Num | 8 | YNF. | 15b. Which room(s) have or have had mold or mildew? - Bedroom(s) |
| 29 | HEQ_1250 | Num | 8 | YNF. | 15c. Which room(s) have or have had mold or mildew? - Living or family room |
| 30 | HEQ_1260 | Num | 8 | YNF. | 15d. Which room(s) have or have had mold or mildew? - Kitchen |
| 31 | HEQ_1270 | Num | 8 | YNF. | 15e. Which room(s) have or have had mold or mildew? - Basement or attic |
| 32 | HEQ_1280 | Num | 8 | YNF. | 15f. Which room(s) have or have had mold or mildew? - Other |
| 33 | HEQ_1290 | Num | 8 | YNF. | 16. Do you ever see cockroaches in the child's home? |
| 34 | HEQ_1300 | Num | 8 | YNF. | 17a. In which room(s) have you seen cockroaches? - Bathroom(s) |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 35 | HEQ_1310 | Num | 8 | YNF. | 17b. In which room(s) have you seen cockroaches? - Bedroom(s) |
| 36 | HEQ_1320 | Num | 8 | YNF. | 17c. In which room(s) have you seen cockroaches? - Living or family room |
| 37 | HEQ_1330 | Num | 8 | YNF. | 17d. In which room(s) have you seen cockroaches? - Kitchen |
| 38 | HEQ_1340 | Num | 8 | YNF. | 17e. In which room(s) have you seen cockroaches? - Basement or attic |
| 39 | HEQ_1350 | Num | 8 | YNF. | 17f. In which room(s) have you seen cockroaches? - Other |
| 40 | HEQ_1360 | Num | 8 | YNF. | 18. Does the child share his/her bedroom with another person? |
| 41 | HEQ_1370 | Num | 8 | | 18a. If YES, how many others? |
| 42 | HEQ_1380 | Num | 8 | HEQ_1380F. | 19. What is the floor covering in the child's bedroom? |
| 43 | HEQ_1390 | Num | 8 | HEQ_1390F. | 19a. If SYNTHETIC OR WOOL CARPET, what type of padding is under the carpet in the child's bedroom? |
| 44 | HEQ_1400 | Num | 8 | HEQ_1400F. | 20. What type of mattress is on the child's bed? |
| 45 | HEQ_1410 | Num | 8 | | 21. How old is the mattress used on the child's bed? (years) |
| 46 | HEQ_1420 | Num | 8 | YNF. | 22. Is the mattress completely enclosed in an allergy-proof, encasing cover? |
| 47 | HEQ_1430 | Num | 8 | YNF. | 23. Does the child's bed have a box spring? |
| 48 | HEQ_1440 | Num | 8 | YNF. | 24. Is the box spring completely enclosed in an allergy-proof, encasing cover? |
| 49 | HEQ_1450 | Num | 8 | HEQ_1450F. | 25. What type of pillow is used on the child's bed? |
| 50 | HEQ_1460 | Num | 8 | | 26. How old is the pillow used on the child's bed? (years) |
| 51 | HEQ_1470 | Num | 8 | YNF. | 27. Is the pillow completely enclosed in an allergy-proof, encasing cover? |
| 52 | HEQ_1480 | Num | 8 | YNF. | 28. Are the child's bed covers or sheets washed in hot water at least 1 time per week? |
| 53 | HEQ_1490 | Num | 8 | YNF. | 29. Does your family have any animals? |
| 54 | HEQ_1500 | Num | 8 | | 30a. Enter the number of animals that the family has Cat |
| 55 | HEQ_1510 | Num | 8 | | 30b. Enter the number of animals that the family has Dog |
| 56 | HEQ_1520 | Num | 8 | | 30c. Enter the number of animals that the family has Rabbit, guinea pig, hamster, gerbil, or mouse |
| 57 | HEQ_1530 | Num | 8 | | 30d. Enter the number of animals that the family has Bird |
| 58 | HEQ_1540 | Num | 8 | | 30e. Enter the number of animals that the family has Other |
| 59 | HEQ_1550 | Num | 8 | YNF. | 31. Are any pets allowed into the child's home? |
| 60 | HEQ_1560 | Num | 8 | YNDKF. | 32a. Which pets are allowed into the child's home? - Cat |
| 61 | HEQ_1570 | Num | 8 | YNDKF. | 32b. Which pets are allowed into the child's home? - Dog |
| 62 | HEQ_1580 | Num | 8 | YNDKF. | 32c. Which pets are allowed into the child's home? - Rabbit, guinea pig, hamster, gerbil, or mouse |
| 63 | HEQ_1590 | Num | 8 | YNDKF. | 32d. Which pets are allowed into the child's home? - Bird |
| 64 | HEQ_1600 | Num | 8 | YNDKF. | 32e. Which pets are allowed into the child's home? - Other |
| 65 | HEQ_1610 | Num | 8 | YNDKF. | 33a. Which pets are allowed into the child's bedroom? - Cat |
| 66 | HEQ_1620 | Num | 8 | YNDKF. | 33b. Which pets are allowed into the child's bedroom? - Dog |
| 67 | HEQ_1630 | Num | 8 | YNDKF. | 33c. Which pets are allowed into the child's bedroom? - Rabbit, guinea pig, hamster, gerbil, or mouse |
| 68 | HEQ_1640 | Num | 8 | YNDKF. | 33d. Which pets are allowed into the child's bedroom? - Bird |
| 69 | HEQ_1650 | Num | 8 | YNDKF. | 33e. Which pets are allowed into the child's bedroom? - Other |

| Num | Variable | Type | Len | Format | Label | |
|-----|----------|------|-----|--|---|--|
| 70 | HEQ_1660 | Num | 8 | YNDKF. 34a. In general and on a regular basis, is the child exposed to any of the following animals for more than one hour each day? - Cat | | |
| 71 | HEQ_1670 | Num | 8 | YNDKF. | 34b. In general and on a regular basis, is the child exposed to any of the following animals for more than one hour each day? - Dog | |
| 72 | HEQ_1680 | Num | 8 | YNDKF. | 34c. In general and on a regular basis, is the child exposed to any of the following animals for more than one hour each day? - Rabbit, guinea pig, hamster, gerbil, or mouse | |
| 73 | HEQ_1690 | Num | 8 | YNDKF. | 34d. In general and on a regular basis, is the child exposed to any of the following animals for more than one hour each day? - Bird | |
| 74 | HEQ_1700 | Num | 8 | YNDKF. | 34e. In general and on a regular basis, is the child exposed to any of the following animals for more than one hour each day? - Other | |

Data Set Name: icd9.sas7bdat

| Num | Variable | Type | Len | Label |
|-----|----------|------|-----|------------------|
| 1 | CODE | Char | 12 | ICD9 Code |
| 2 | DESC | Char | 26 | ICD9 Description |

Data Set Name: ios.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | IOS_1000 | Num | 8 | YNF. | 1. During the past 24 hours, has the participant used sustained-release theophylline? |
| 5 | IOS_1010 | Num | 8 | YNF. | 2. During the past 12 hours, has the participant used a long-acting bronchodilator (i.e., salmetrerol)? |
| 6 | IOS_1020 | Num | 8 | YNF. | 3. During the past 4 hours, has the participant used a short-acting bronchodilator? |
| 7 | IOS_1030 | Num | 8 | YNF. | 4. During the past 2 weeks, has the participant had any respoiratory infections, colds, or bronchitis? |
| 8 | IOS_1035 | Num | 8 | YNF. | 5. Is there any other reason the participant should not proceed with the pulmonary function testing? |
| 9 | IOS_1040 | Num | 8 | YNF. | 6. Is the participant eligible to proceed with the pulmonary function testing? |
| 10 | IOS_1050 | Num | 8 | | 7. Standing height |
| 11 | IOS_1055 | Num | 8 | YNF. | 8. Did the participant refuse to perform the procedure? |
| 12 | IOS_1060 | Num | 8 | | 9. Time IOS started |
| 13 | IOS_1080 | Num | 8 | | 10a. Results of first effort - R5 |
| 14 | IOS_1085 | Num | 8 | | 10b. Results of first effort - R10 |
| 15 | IOS_1090 | Num | 8 | | 10c. Results of first effort - R15 |
| 16 | IOS_1100 | Num | 8 | | 10d. Results of first effort - R35 |
| 17 | IOS_1110 | Num | 8 | | 10e. Results of first effort - X5 |
| 18 | IOS_1120 | Num | 8 | | 10f. Results of first effort - Resonant Frequency |
| 19 | IOS_1130 | Num | 8 | | 10g. Results of first effort - Area XA |
| 20 | IOS_1140 | Num | 8 | | 14. Time bronchdilator given |
| 21 | IOS_1150 | Num | 8 | | 15. Time postbronchdilator IOS started |
| 22 | IOS_1160 | Num | 8 | | 16a. Results of first effort - R5 |
| 23 | IOS_1165 | Num | 8 | | 16b. Results of first effort - R10 |
| 24 | IOS_1170 | Num | 8 | | 16c. Results of first effort - R15 |
| 25 | IOS_1180 | Num | 8 | | 16d. Results of first effort - R35 |
| 26 | IOS_1190 | Num | 8 | | 16e. Results of first effort - X5 |
| 27 | IOS_1200 | Num | 8 | | 16f. Results of first effort - Resonant Frequency |
| 28 | IOS_1210 | Num | 8 | | 16g. Results of first effort - Area XA |
| 29 | IOS_1220 | Num | 8 | YNF. | 19. In your judgement, was the participant's prebronchodilator technique acceptable? |
| 30 | IOS_1230 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Coherence < 0.80 (for R10) |
| 31 | IOS_1240 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Less than 3 good tests |
| 32 | IOS_1250 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Inconsistent tidal breathing |
| 33 | IOS_1260 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Participant refusal during test |
| 34 | IOS_1270 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Other |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------------|--|
| 35 | IOS_1280 | Num | 8 | IOS_1600_1280F. | 19b. If YES, grade the participant's technique. |
| 36 | IOS_1290 | Num | 8 | | 11a. Results of second effort - R5 |
| 37 | IOS_1295 | Num | 8 | | 11b. Results of second effort - R10 |
| 38 | IOS_1300 | Num | 8 | | 11c. Results of second effort - R15 |
| 39 | IOS_1310 | Num | 8 | | 11d. Results of second effort - R35 |
| 40 | IOS_1320 | Num | 8 | | 11e. Results of second effort - X5 |
| 41 | IOS_1330 | Num | 8 | | 11f. Results of second effort - Resonant Frequency |
| 42 | IOS_1340 | Num | 8 | | 11g. Results of second effort - Area XA |
| 43 | IOS_1350 | Num | 8 | | 12a. Results of third effort - R5 |
| 44 | IOS_1355 | Num | 8 | | 12b. Results of third effort - R10 |
| 45 | IOS_1360 | Num | 8 | | 12c. Results of third effort - R15 |
| 46 | IOS_1370 | Num | 8 | | 12d. Results of third effort - R35 |
| 47 | IOS_1380 | Num | 8 | | 12e. Results of third effort - X5 |
| 48 | IOS_1390 | Num | 8 | | 12f. Results of third effort - Resonant Frequency |
| 49 | IOS_1400 | Num | 8 | | 12g. Results of third effort - Area XA |
| 50 | IOS_1410 | Num | 8 | | 17a. Results of second effort - R5 |
| 51 | IOS_1415 | Num | 8 | | 17b. Results of second effort - R10 |
| 52 | IOS_1420 | Num | 8 | | 17c. Results of second effort - R15 |
| 53 | IOS_1430 | Num | 8 | | 17d. Results of second effort - R35 |
| 54 | IOS_1440 | Num | 8 | | 17e. Results of second effort - X5 |
| 55 | IOS_1450 | Num | 8 | | 17f. Results of second effort - Resonant Frequency |
| 56 | IOS_1460 | Num | 8 | | 17g. Results of second effort - Area XA |
| 57 | IOS_1470 | Num | 8 | | 18a. Results of third effort - R5 |
| 58 | IOS_1475 | Num | 8 | | 18b. Results of third effort - R10 |
| 59 | IOS_1480 | Num | 8 | | 18c. Results of third effort - R15 |
| 60 | IOS_1490 | Num | 8 | | 18d. Results of third effort - R35 |
| 61 | IOS_1500 | Num | 8 | | 18e. Results of third effort - X5 |
| 62 | IOS_1510 | Num | 8 | | 18f. Results of third effort - Resonant Frequency |
| 63 | IOS_1520 | Num | 8 | | 18g. Results of third effort - Area XA |
| 64 | IOS_1530 | Num | 8 | YNF. | 13. In your judgement, was the participant's prebronchodilator technique acceptable? |
| 65 | IOS_1540 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Coherence < 0.80 (for R10) |
| 66 | IOS_1550 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Poor repeatability (R10 values vary by more than 20%) |
| 67 | IOS_1560 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Less than 3 good tests |
| 68 | IOS_1570 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Inconsistent tidal breathing |
| 69 | IOS_1580 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Participant refusal during test |
| 70 | IOS_1590 | Num | 8 | YNF. | 13a. If NO, why was it unacceptable? Other |
| 71 | IOS_1600 | Num | 8 | IOS_1600_1280F. | 13b. If YES, grade the participant's technique. |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|--|
| 72 | IOS_1235 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Poor repeatability (R10 values vary by more than 20%) |
| 73 | IOS_1610 | Num | 8 | IOS_1610F. | 20. How was the participant positioned? |
| 74 | IOS_1620 | Num | 8 | YNF. | 21. Were the participant's cheeks held? |
| 75 | IOS_1630 | Num | 8 | IOS_1630F. | 21a. If YES, how were the participant's cheeks held? |
| 76 | IOS_1640 | Num | 8 | YNF. | 22. Were nose clips used? |
| 77 | IOS_1650 | Num | 8 | IOS_1650F. | 22a. If YES, how effective were the nose clips? |
| 78 | IOS_1660 | Num | 8 | YNF. | 22b. If NO, was the nose occluded? |
| 79 | IOS_1670 | Num | 8 | IOS_1670F. | 22bi. If YES, how was the nose occluded? |
| 80 | IOS_1680 | Num | 8 | YNF. | 23. Were there problems with the use of the standard mouthpiece? |

Data Set Name: jun_acq.sas7bdat

| Num | Variable | Type | Len | Format | Label | |
|-----|----------|------|-----|------------|--|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID | |
| 2 | VNUM | Num | 8 | | Visit Number | |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) | |
| 4 | JUN_1000 | Num | 8 | JUN_1000F. | 1. Who is the respondent? | |
| 5 | JUN_1010 | Num | 8 | JUN_1010F. | 2. On average, during the past week, how often were you awakened by your asthma during the night? | |
| 6 | JUN_1020 | Num | 8 | JUN_1020F. | 3. On average, during the past week, how bad were your asthma symptoms when you woke up in the morning? | |
| 7 | JUN_1030 | Num | 8 | JUN_1030F. | 4. In general, during the past week, how limited were you in your activities because of your asthma? | |
| 8 | JUN_1040 | Num | 8 | JUN_1040F. | 5. In general, during the past week, how much shortness of breath did you experience because of your asthma? | |
| 9 | JUN_1050 | Num | 8 | JUN_1050F. | 6. In general, during the past week, how much of the time did you wheeze? | |
| 10 | JUN_1060 | Num | 8 | JUN_1060F. | 7. On average, during the past week, how many puffs of short-acting bronchodilator (e.g. Ventolin) have you used each day? | |
| 11 | JUN_1110 | Num | 8 | YNF. | 8. Were pre-bronchodilator FEV1 and FEB1% predicted measures completed? | |
| 12 | JUN_1130 | Num | 8 | | Respondent Initials Date (number of days since enrollment date) | |

Data Set Name: lab.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | LAB_1000 | Num | 8 | LAB_1000F. | 1. Pregnancy test results |
| 5 | LAB_1020 | Num | 8 | | Participant's Initials Date (number of days since enrollment date) |
| 6 | LAB_1030 | Num | 8 | | 2. BLOOD TESTS - SGPT/ALT |
| 7 | LAB_1040 | Num | 8 | | 3. BLOOD TESTS - SGOT/AST |
| 8 | LAB_1050 | Num | 8 | | 4. BLOOD TESTS - Total Bilirubin |
| 9 | LAB_1060 | Num | 8 | | 5. BLOOD TESTS - Total WBC |
| 10 | LAB_1070 | Num | 8 | | 6. BLOOD TESTS - Eosinophils |
| 11 | LAB_1075 | Num | 8 | | 7. BLOOD TESTS - Hematocrit |

Data Set Name: mataq.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | MAT_1000 | Num | 8 | MAT_1000F. | 1. Who is the respondent? |
| 5 | MAT_1010 | Num | 8 | MAT_1010_1050F. | 2a. Since the last study visit, how many days did the participant: Have wheezing or difficulty breathing when playing or exercising? |
| 6 | MAT_1020 | Num | 8 | MAT_1010_1050F. | 2b. Since the last study visit, how many days did the participant: Have wheezing during the day when not playing or exercising? |
| 7 | MAT_1030 | Num | 8 | MAT_1010_1050F. | 2c. Since the last study visit, how many days did the participant: Wake up at night with wheezing or difficult breathing? |
| 8 | MAT_1040 | Num | 8 | MAT_1010_1050F. | 2d. Since the last study visit, how many days did the participant: Miss days of school or work because of his/her asthma? |
| 9 | MAT_1050 | Num | 8 | MAT_1010_1050F. | 2e. Since the last study visit, how many days did the participant: Miss any daily activities (for example, playing or exercising, going to a friend's house, or any family activity) because of his/her asthma? |
| 10 | MAT_1060 | Num | 8 | YNUF. | 3a. Do you believe: The participant's asthma was well controlled since the last study visit? |
| 11 | MAT_1070 | Num | 8 | YNUF. | 3b. Do you believe: The participant is able to take the study medicine(s) as directed? |
| 12 | MAT_1080 | Num | 8 | YNUF. | 3c. Do you believe: The study medicine(s) the participant takes are useful for controlling asthma? |
| 13 | MAT_1090 | Num | 8 | MAT_1090F. | 4. Since the last study visit, on days the participant used albuterol for quick relief, how many puffs a day did he or she usually take? |
| 14 | MAT_1100 | Num | 8 | MAT_1100F. | 5. Since the last study visit, what was the greatest number of puffs of albuterol in one day the participant used for quick relief from asthma symptoms? |
| 15 | MAT_1110 | Num | 8 | MAT_1110F. | 6. Since the last study visit, what was the greatest number of nebulizer treatments with albuterol the participant used in one day for quick relief from asthma symptoms? |
| 16 | MAT_1130 | Num | 8 | | Respondent Initials Date (number of days since enrollment date) |

Data Set Name: maxbd.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | MAX_1000 | Num | 8 | YNF. | 1. During the past 2 weeks, has the child had any respiratory infections, colds, or bronchitis? |
| 5 | MAX_1010 | Num | 8 | YNF. | 2. During the past 48 hours, has the child used any oral decongestants or cold remedies? |
| 6 | MAX_1020 | Num | 8 | YNF. | 3. During the past 4 hours, has the child consumed caffeine? |
| 7 | MAX_1030 | Num | 8 | YNF. | 4. During the past 8 hours, has the child used medications with caffeine? |
| 8 | MAX_1040 | Num | 8 | YNF. | 5. During the past 12 hours, has the child used a long-acting inhaled beta-agonist (e.g. Serevent, formoterol)? |
| 9 | MAX_1050 | Num | 8 | YNF. | 6. During the past 24 hours, has the child used sustained-release theophylline? |
| 10 | MAX_1060 | Num | 8 | YNF. | 7. During the past 4 hours, has the child used a short-acting bronchodilator? |
| 11 | MAX_1070 | Num | 8 | YNF. | 8. Is there any other reason the child should not proceed with the pulmonary function testing? |
| 12 | MAX_1080 | Num | 8 | YNF. | 9. Is the child eligible to proceed with the pulmonary function testing? |
| 13 | MAX_1090 | Num | 8 | | 10. Standing height (barefoot or thin socks) |
| 14 | MAX_1100 | Num | 8 | | 11. Time spirometry started |
| 15 | MAX_1110 | Num | 8 | | 12a. Results of best effort: FVC |
| 16 | MAX_1120 | Num | 8 | | 12b. Results of best effort: FEV1 |
| 17 | MAX_1130 | Num | 8 | | 12c. Results of best effort: FEV1 (% predicted) |
| 18 | MAX_1140 | Num | 8 | | 12d. Results of best effort: FEV1/FVC |
| 19 | MAX_1150 | Num | 8 | | 12e. Results of best effort: FEF25-75 |
| 20 | MAX_1160 | Num | 8 | | 12f. Results of best effort: FEF50 |
| 21 | MAX_1170 | Num | 8 | | 12g. Results of best effort: FEF75 |
| 22 | MAX_1180 | Num | 8 | | 12h. Results of best effort: Peak flow from best effort |
| 23 | MAX_1190 | Num | 8 | | 12i. Results of best effort: FET |
| 24 | MAX_1200 | Num | 8 | | 12j. Results of best effort: FET (Peak Flow) |
| 25 | MAX_1210 | Num | 8 | | 12k. Results of best effort: V backextrapolation ex |
| 26 | MAX_1220 | Num | 8 | | 121. Results of best effort: V backextrapolation % FVC |
| 27 | MAX_1230 | Num | 8 | | 12m. Results of best effort: ATS Accepted |
| 28 | MAX_1240 | Num | 8 | | 12n. Results of best effort: ATS Error Code |
| 29 | MAX_1250 | Num | 8 | | 13. Time albuterol administered |
| 30 | MAX_1260 | Num | 8 | | 14a. Child's FEV1 after 4 puffs of albuterol: Time spirometry started |
| 31 | MAX_1270 | Num | 8 | | 14b. Child's FEV1 after 4 puffs of albuterol: FEV1 |
| 32 | MAX_1280 | Num | 8 | | 14c. Child's FEV1 after 4 puffs of albuterol: FEV1 (% predicted) |
| 33 | MAX_1290 | Num | 8 | | 15. Time albuterol administered |
| 34 | MAX_1300 | Num | 8 | | 16a. Child's FEV1 after additional 2 puffs of albuterol: Time spirometry started |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 35 | MAX_1310 | Num | 8 | | 16b. Child's FEV1 after additional 2 puffs of albuterol: FEV1 |
| 36 | MAX_1320 | Num | 8 | | 16c. Child's FEV1 after additional 2 puffs of albuterol: FEV1 (% predicted) |
| 37 | MAX_1330 | Num | 8 | | 16d. Child's FEV1 after additional 2 puffs of albuterol: Percent difference in FEV1 ((Question #16b - Question #14b) / (Question #14b)) x 100 |
| 38 | MAX_1340 | Num | 8 | YNF. | 16e. Child's FEV1 after additional 2 puffs of albuterol: Is the percent difference in Question #16d <= 5.0%? |
| 39 | MAX_1350 | Num | 8 | | 17. Time albuterol administered |
| 40 | MAX_1360 | Num | 8 | | 18a. Child's FEV1 after last 2 puffs of albuterol: Time spirometry started |
| 41 | MAX_1370 | Num | 8 | | 18b. Child's FEV1 after last 2 puffs of albuterol: FEV1 |
| 42 | MAX_1380 | Num | 8 | | 18c. Child's FEV1 after last 2 puffs of albuterol: FEV1 (% predicted) |
| 43 | MAX_1390 | Num | 8 | YNF. | 19. In your judgement, was the child's technique acceptable? |
| 44 | MAX_1400 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Inadequate inspiratory effort |
| 45 | MAX_1410 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Inadequate expiratory effort |
| 46 | MAX_1420 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Inadequate duration of expiration |
| 47 | MAX_1430 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Cough during procedure |
| 48 | MAX_1440 | Num | 8 | YNF. | 19a. If NO, why was it unacceptable? Other (specify) |
| 49 | MAX_1450 | Num | 8 | MAX_1450F. | 19b. If YES, grade the child's technique. |

Data Set Name: med.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | MED_1000 | Num | 8 | MED_1000F. | 1. What type of visit is this? |
| 5 | MED_1040 | Num | 8 | | Flag: Coordinator signature |
| 6 | MED_1050 | Num | 8 | | Coordinator signature Date (number of days since enrollment date) |

Data Set Name: medcodes.sas7bdat

| Num | Variable | Type | Len | Label |
|-----|----------|------|-----|---------------------------|
| 1 | CATEGORY | Char | 50 | Drug Category Description |
| 2 | BRAND_NM | Char | 48 | Brand Name Description |
| 3 | GENER_NM | Char | 50 | Generic Name Description |
| 4 | DRUGCODE | Num | 8 | Drug Code |

Data Set Name: medhx2.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|------------|------|-----|------------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | MHX_1000 | Num | 8 | MHX_1000F. | 1. What is your relationship to the child? |
| 5 | MHX_1015 | Num | 8 | MHX_1015F. | 3a. What is the child's ethnic background? |
| 6 | RACE_BLACK | Num | 8 | YNF. | RACE: Black/African American |
| 7 | RACE_WHITE | Num | 8 | YNF. | RACE: White |
| 8 | MHX_1030 | Num | 8 | MHX_1030F. | 4. What is the child's gender? |
| 9 | MHX_1040 | Num | 8 | YNF. | 5. Has a doctor or other health practitioner ever said that the child has heart disease? |
| 10 | MHX_1050 | Num | 8 | YNF. | 6. During the past 12 months, did the child have any illnesses other than asthma (do not count minor colds or allergies)? |
| 11 | MHX_1060 | Num | 8 | YNF. | 7. During the past 12 months, has the child had any asthma symptoms? |
| 12 | MHX_1061 | Num | 8 | YNF. | 7ai. If YES, what were the child's symptoms: Wheezing |
| 13 | MHX_1062 | Num | 8 | YNF. | 7aii. If YES, what were the child's symptoms: Coughing |
| 14 | MHX_1063 | Num | 8 | YNF. | 7aiii. If YES, what were the child's symptoms: Shortness of breath |
| 15 | MHX_1064 | Num | 8 | YNF. | 7aiv. If YES, what were the child's symptoms: Chest tightness |
| 16 | MHX_1065 | Num | 8 | YNF. | 7av. If YES, what were the child's symptoms: Other |
| 17 | MHX_1070 | Num | 8 | YNF. | 8a. During the past 12 months, has the child had: Pneumonia |
| 18 | MHX_1080 | Num | 8 | YNF. | 8b. During the past 12 months, has the child had: Sinusitis |
| 19 | MHX_1160 | Num | 8 | YNF. | 9. During the past 12 months has the child had any chronic symptoms that affected his/her nose, eyes, or sinuses? |
| 20 | MHX_1170 | Num | 8 | MHX_1170_1290F. | 9a. During the past 12 months, how would you generally describe these chronic symptoms? |
| 21 | MHX_1180 | Num | 8 | MHX_1180TO1190F. | 10. During the past 12 months, how frequently has the child used antihistamines and/or decongestants to treat nose, eye, and sinus symptoms (prescription or over the counter)? |
| 22 | MHX_1190 | Num | 8 | MHX_1180TO1190F. | 11. During the past 12 months, how frequently has the child used nasal steroids to treat nose, and sinus symptoms? |
| 23 | MHX_1200 | Num | 8 | | 12. During the past 12 months, how many times have you contacted or visited a doctor because of problems with the child's nose, eyes, or sinuses? |
| 24 | MHX_1210 | Num | 8 | | 13. During the past 12 months, how many times has the child had a sinus infection that required treatment with antibiotics? |
| 25 | MHX_1220 | Num | 8 | | 14. During the past 12 months, how many times has the child had a sinus infection that required treatment with an oral steroid? |
| 26 | MHX_1230 | Num | 8 | YNF. | 15. Has the child ever had sinus surgery? |
| 27 | MHX_1240 | Num | 8 | YNF. | 16. Has the child ever been diagnosed with eczema (atopic dermatitis) by a physician? |
| 28 | MHX_1250 | Num | 8 | YNF. | 17a. Which parts of the child's body were ever affected by eczema? Head |
| 29 | MHX_1260 | Num | 8 | YNF. | 17b. Which parts of the child's body were ever affected by eczema? Arms/Hands |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------------|---|
| 30 | MHX_1270 | Num | 8 | YNF. | 17c. Which parts of the child's body were ever affected by eczema? Trunk (mid-section or torso) |
| 31 | MHX_1280 | Num | 8 | YNF. | 17d. Which parts of the child's body were ever affected by eczema? Legs/Feet |
| 32 | MHX_1285 | Num | 8 | YNF. | 17e. Which parts of the child's body were ever affected by eczema? Other |
| 33 | MHX_1290 | Num | 8 | MHX_1170_1290F. | 18. How would you desribe your child's worst case of eczema? |
| 34 | MHX_1300 | Num | 8 | YNDKF. | 19a. Has a doctor ever said that the [BIOLOGICAL] father of the child had: Asthma |
| 35 | MHX_1310 | Num | 8 | YNDKF. | 19b. Has a doctor ever said that the [BIOLOGICAL] father of the child had: Hay fever, eczema, or other atopic disorder? |
| 36 | MHX_1320 | Num | 8 | YNDKF. | 19c. Has a doctor ever said that the [BIOLOGICAL] father of the child had: Chronic bronchitis, emphysema, chronic obstructive lung disease,or cystic fibrosis? |
| 37 | MHX_1330 | Num | 8 | YNDKF. | 20a. Has a doctor ever said that the [BIOLOGICAL] mother of the child had: Asthma |
| 38 | MHX_1340 | Num | 8 | YNDKF. | 20b. Has a doctor ever said that the [BIOLOGICAL] mother of the child had: Hay fever, eczema, or other atopic disorder? |
| 39 | MHX_1350 | Num | 8 | YNDKF. | 20c. Has a doctor ever said that the [BIOLOGICAL] mother of the child had: Chronic bronchitis, emphysema, chronic obstructive lung disease, or cystic fibrosis? |
| 40 | MHX_1360 | Num | 8 | YNF. | 21. Does the child have a [BIOLOGICAL] sibling? (Include half siblings) |
| 41 | MHX_1370 | Num | 8 | YNDKF. | 22a. Has a doctor ever said that the [BIOLOGICAL] sibling of the child had: Asthma (Include half siblings) |
| 42 | MHX_1380 | Num | 8 | YNDKF. | 22b. Has a doctor ever said that the [BIOLOGICAL] sibling of the child had: Hay fever, eczema, or other atopic disorder? (Include half siblings) |
| 43 | MHX_1390 | Num | 8 | YNDKF. | 22c. Has a doctor ever said that the [BIOLOGICAL] sibling of the child had: Chronic bronchitis, emphysema, chronic obstructive lung disease, or cystic fibrosis? (Include half siblings) |
| 44 | MHX_1400 | Num | 8 | YNDKF. | 23. Did the child's mother smoke while she was pregnant with this child? |
| 45 | MHX_1410 | Num | 8 | YNDKF. | 24a. During which part(s) of the pregnancy did the child's mother smoke? - First 3 months |
| 46 | MHX_1420 | Num | 8 | YNDKF. | 24b. During which part(s) of the pregnancy did the child's mother smoke? - Middle 3 months |
| 47 | MHX_1430 | Num | 8 | YNDKF. | 24c. During which part(s) of the pregnancy did the child's mother smoke? - Last 3 months |
| 48 | MHX_1440 | Num | 8 | YNDKF. | 25a. Between the time the child was born and he/she turned two years old, did the child's mother (or stepmother or female guardian) smoke? |
| 49 | MHX_1450 | Num | 8 | YNDKF. | 25b. Between the time the child was born and he/she turned two years old, did the child's father (or stepfather or male guardian) smoke? |
| 50 | MHX_1460 | Num | 8 | YNDKF. | 25c. Between the time the child was born and he/she turned two years old, were there any other smokers in the household? (Include visitors, such as grandparents or babysitters, who visited at least weekly) |
| 51 | MHX_1470 | Num | 8 | YNDKF. | 26a. Since the child turned two years old and until the present time OR until the start of first grade, did the child's mother (or stepmother or female guardian) smoke? |

| Num | Variable | Type | Len | Format | Label |
|-----|------------|------|-----|--------|---|
| 52 | MHX_1480 | Num | 8 | YNDKF. | 26b. Since the child turned two years old and until the present time OR until the start of first grade, did the child's father (or stepfather or male guardian)? |
| 53 | MHX_1490 | Num | 8 | YNDKF. | 26c. Since the child turned two years old and until the present time OR until the start of first grade, were there any other smokers in the household? (Incl. visitors, such as grandparents or babysitters, who visited at least weekly) |
| 54 | AGE | Num | 8 | | |
| 55 | RACE_OTHER | Num | 8 | YNF. | RACE: American Indian/Alaskan Native, Asian, or Native Hawai'ian/Other Pacific Islander |

Data Set Name: metha.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | MTH_1000 | Num | 8 | YNF. | 1. During the past 4 weeks, has the child had any respiratory infections (i.e., upper respiratory infection, cold, or bronchitis)? |
| 5 | MTH_1010 | Num | 8 | YNF. | 2. Has it been less than 4 weeks since the child last took an oral steroid (i.e., prednisolone, prednisone)? |
| 6 | MTH_1020 | Num | 8 | YNF. | 3. During the past 4 weeks, has the child had any other severe acute illness? |
| 7 | MTH_1030 | Num | 8 | YNF. | 3. If YES, has the child received permission from the supervising physician to proceed with the methacholine challenge testing? |
| 8 | MTH_1040 | Num | 8 | YNF. | 4. Is the child currently having an acute asthma attack? |
| 9 | MTH_1050 | Num | 8 | YNF. | 5. During the past 24 hours, has the child used sustained-release theophylline? |
| 10 | MTH_1060 | Num | 8 | YNF. | 6. During the past 12 hours, has the child used a long-acting bronchodilator (i.e., salmeterol)? |
| 11 | MTH_1070 | Num | 8 | YNF. | 7. During the past 4 hours, has the child used a short-acting bronchodilator? |
| 12 | MTH_1080 | Num | 8 | YNF. | 8. During the past 4 hours, has the child had any caffeine (i.e., chocolcate, cola drinks, caffeinated coffee or tea, or medication with caffeine)? |
| 13 | MTH_1090 | Num | 8 | YNF. | 9. Is the child using any anti-inflammatories? |
| 14 | MTH_1100 | Num | 8 | | 9a. Inhaled corticosteroid |
| 15 | MTH_1110 | Num | 8 | | 9a. Inhaled corticosteroid - Date (number of days since enrollment date) |
| 16 | MTH_1120 | Num | 8 | | 9a. Cromolyn/nedocromil |
| 17 | MTH_1130 | Num | 8 | | 9a. Cromolyn/nedocromil - Date (number of days since enrollment date) |
| 18 | MTH_1140 | Num | 8 | | 9a. Leukotriene receptor antagonists |
| 19 | MTH_1150 | Num | 8 | | 9a. Leukotriene receptor antagonists - Date (number of days since enrollment date) |
| 20 | MTH_1160 | Num | 8 | YNF. | 10. Does the child have a baseline (pre-diluent) FEV1 less than 70% of predicted FEV1? |
| 21 | MTH_1170 | Num | 8 | YNF. | 11. Is there any other reson you should not proceed with the methacholine challenge? |
| 22 | MTH_1180 | Num | 8 | YNF. | 12. Is the child eligible to proceed with the diluent (solution #0) pulmonary function testing for the methacholine challenge? |
| 23 | MTH_1190 | Num | 8 | | 13. Standing height (barefoot or thin socks) - cm |
| 24 | MTH_1210 | Num | 8 | YNF. | 14. Was baseline (pre-diluent) spirometry completed? |
| 25 | MTH_1280 | Num | 8 | | 15. Earliest expiration date of all 10 methacholine solutions (number of days since enrollment date) |
| 26 | MTH_1290 | Num | 8 | | 16a. FVC/FEV1 for serial challenges Solution 0 (diluent) - FEV1 |
| 27 | MTH_1300 | Num | 8 | | 16a. FVC/FEV1 for serial challenges Solution 0 (diluent) - FVC |
| 28 | MTH_1310 | Num | 8 | | 16b. FVC/FEV1 for serial challenges Solution 1 (0.098 mg/ml) - FEV1 |
| 29 | MTH_1320 | Num | 8 | | 16b. FVC/FEV1 for serial challenges Solution 1 (0.098 mg/ml) - FVC |
| 30 | MTH_1330 | Num | 8 | | 16c. FVC/FEV1 for serial challenges Solution 2 (0.195 mg/ml) - FEV1 |
| 31 | MTH_1340 | Num | 8 | | 16c. FVC/FEV1 for serial challenges Solution 2 (0.195 mg/ml) - FVC |
| 32 | MTH_1350 | Num | 8 | | 16d. FVC/FEV1 for serial challenges Solution 3 (0.391 mg/ml) - FEV1 |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------|--|
| 33 | MTH_1360 | Num | 8 | | 16d. FVC/FEV1 for serial challenges Solution 3 (0.391 mg/ml) - FVC |
| 34 | MTH_1370 | Num | 8 | | 16e. FVC/FEV1 for serial challenges Solution 4 (0.781 mg/ml) - FEV1 |
| 35 | MTH_1380 | Num | 8 | | 16e. FVC/FEV1 for serial challenges Solution 4 (0.781 mg/ml) - FVC |
| 36 | MTH_1390 | Num | 8 | | 16f. FVC/FEV1 for serial challenges Solution 5 (1.563 mg/ml) - FEV1 |
| 37 | MTH_1400 | Num | 8 | | 16f. FVC/FEV1 for serial challenges Solution 5 (1.563 mg/ml) - FVC |
| 38 | MTH_1410 | Num | 8 | | 16g. FVC/FEV1 for serial challenges Solution 6 (3.125 mg/ml) - FEV1 |
| 39 | MTH_1420 | Num | 8 | | 16g. FVC/FEV1 for serial challenges Solution 6 (3.125 mg/ml) - FVC |
| 40 | MTH_1430 | Num | 8 | | 16h. FVC/FEV1 for serial challenges Solution 7 (6.25 mg/ml) - FEV1 |
| 41 | MTH_1440 | Num | 8 | | 16h. FVC/FEV1 for serial challenges Solution 7 (6.25 mg/ml) - FVC |
| 42 | MTH_1450 | Num | 8 | | 16i. FVC/FEV1 for serial challenges Solution 8 (12.5 mg/ml) - FEV1 |
| 43 | MTH_1460 | Num | 8 | | 16i. FVC/FEV1 for serial challenges Solution 8 (12.5 mg/ml) - FVC |
| 44 | MTH_1470 | Num | 8 | | 16j. FVC/FEV1 for serial challenges Solution 9 (25 mg/ml) - FEV1 |
| 45 | MTH_1480 | Num | 8 | | 16j. FVC/FEV1 for serial challenges Solution 9 (25 mg/ml) - FVC |
| 46 | MTH_1490 | Num | 8 | | 17. PC20 |
| 47 | MTH_1500 | Num | 8 | | 17a. Time methacholine challenge was completed (based on 24-hour clock) |
| 48 | MTH_1510 | Num | 8 | | 18a. FEV1 |
| 49 | MTH_1530 | Num | 8 | | 18b. Time of FEV1 in Question #18a (based on 24-hour clock) |
| 50 | MTH_1540 | Num | 8 | YNF. | 18c. Was the FEV1 from Question $\#18a >=$ the Methacholine Reversal Reference Value in the gray box on page 2 of this form? |
| 51 | MTH_1550 | Num | 8 | YNF. | 19. Was additional treatment used in the first hour? |
| 52 | MTH_1560 | Num | 8 | YNF. | 19a. Additional albuterol by MDI |
| 53 | MTH_1570 | Num | 8 | NUMPUFFF. | 19ai. Number of additional puffs of albuterol administered |
| 54 | MTH_1580 | Num | 8 | YNF. | 19b. Nebulized beta-agonist |
| 55 | MTH_1590 | Num | 8 | YNF. | 19c. Subcutaneous epinephrine |
| 56 | MTH_1600 | Num | 8 | YNF. | 19d. Implementation of clinic emergency protocol or algorithm |
| 57 | MTH_1610 | Num | 8 | YNF. | 19e. Other |
| 58 | MTH_1620 | Num | 8 | | 20a. FEV1 |
| 59 | MTH_1640 | Num | 8 | | 20b. Time of FEV1 in Question #20a (based on 24-hour clock) |
| 60 | MTH_1650 | Num | 8 | YNF. | 20c. Was the FEV1 from Question $\#20a >=$ the Methacholine Reversal Reference Value in the gray box on page 2 of this form? |
| 61 | MTH_1660 | Num | 8 | YNF. | 21. Was additional treatment used after one hour? |
| 62 | MTH_1670 | Num | 8 | YNF. | 21a. Additional albuterol by MDI |
| 63 | MTH_1680 | Num | 8 | NUMPUFFF. | 21ai. Number of additional puffs of albuterol administered |
| 64 | MTH_1690 | Num | 8 | YNF. | 21b. Nebulized beta-agonist |
| 65 | MTH_1700 | Num | 8 | YNF. | 21c. Subcutaneous epinephrine |
| 66 | MTH_1710 | Num | 8 | YNF. | 21d. Implementation of clinic emergency protocol or algorithm |
| 67 | MTH_1720 | Num | 8 | YNF. | 21e. Treatment in the emergency room |
| 68 | MTH_1730 | Num | 8 | YNF. | 21f. Overnight hospitalization |
| 69 | MTH_1740 | Num | 8 | YNF. | 21g. Other |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 70 | MTH_1750 | Num | 8 | | 22a. FEV1 |
| 71 | MTH_1770 | Num | 8 | | 22b. Time of FEV1 in Question #22a (based on 24-hour clock) |
| 72 | MTH_1780 | Num | 8 | YNF. | 22c. Was the FEV1 from Question #22a >= the Methacholine Reversal Reference Value in the gray box on page 2 of this form? |
| 73 | MTH_1790 | Num | 8 | | Flag: Physician/CC signature |
| 74 | MTH_1800 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) |

Data Set Name: phone.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | PHN_1000 | Num | 8 | | 1. How many nights did the participant wake up because of asthma? |
| 5 | PHN_1010 | Num | 8 | | 2. On how many days was the participant's AM peak flow in the red zone? |
| 6 | PHN_1020 | Num | 8 | | 3. On how many days was the participant's PM peak flow in the red zone? |
| 7 | PHN_1030 | Num | 8 | | 4. On how many days did the participant rate his/her coughing from asthma as 3 (severe)? |
| 8 | PHN_1040 | Num | 8 | | 5. On how many days did the participant rate his/her wheezing as 3 (severe)? |
| 9 | PHN_1050 | Num | 8 | | 6. On how many days did the participant take 9 or more puffs from the Rescue inhaler for asthma signs or low peak flow? |
| 10 | PHN_1060 | Num | 8 | YNF. | 7. Since the last study visit, not counting hospitalizations, did the participant have an uscheduled doctor or health care provider visit because of acute asthma? |
| 11 | PHN_1070 | Num | 8 | | 7a. If YES, how many visits? |
| 12 | PHN_1080 | Num | 8 | YNF. | 8. Since the last study visit, has the participant been hospitalized for asthma? |
| 13 | PHN_1090 | Num | 8 | YNF. | 9. Do you have any questions that I can help to answer? |

Data Set Name: phy_exam.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|----------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | PX_1000 | Num | 8 | YNF. | 1. Was the Harpenden stadiometer calibrated, per CARE MOP, immediately prior to the visit? |
| 5 | PX_1010 | Num | 8 | | 2. Time measurements started (based on 24-hour clock) |
| 6 | PX_1020 | Num | 8 | | 3a. Standing height (barefoot or thin socks) First - measurement (cm) |
| 7 | PX_1030 | Num | 8 | | 3b. Standing height (barefoot or thin socks) Second - measurement (cm) |
| 8 | PX_1040 | Num | 8 | | 3c. Standing height (barefoot or thin socks) Third - measurement (cm) |
| 9 | PX_1041 | Num | 8 | | 3d. Standing height (barefoot or thin socks) Average height measurement (cm) |
| 10 | PX_1050 | Num | 8 | | 4. Weight (shoes off, light clothing) (kg) |
| 11 | PX_1045 | Num | 8 | YNF. | 3e. In your judgement, was the subject's height measurement acceptable? |
| 12 | PX_1060 | Num | 8 | YNF. | 5. Resting blood pressure - systolic (mm Hg) |
| 13 | PX_1070 | Num | 8 | | 5. Resting blood pressure - diastolic (mm Hg) |
| 14 | PX_1080 | Num | 8 | YNF. | 6. Is chest auscultation clear? |
| 15 | PX_1090 | Num | 8 | YNF. | 6a. Slight expiratory wheeze |
| 16 | PX_1100 | Num | 8 | YNF. | 6b. Loud expiratory wheeze |
| 17 | PX_1110 | Num | 8 | YNF. | 6c. Inspiratory and expiratory wheezes |
| 18 | PX_1120 | Num | 8 | YNF. | 6d. Acute respiratory distress |
| 19 | PX_1130 | Num | 8 | YNF. | 6e. Rales and/or rhonchi |
| 20 | PX_1140 | Num | 8 | YNF. | 6f. Crackles |
| 21 | PX_1150 | Num | 8 | YNF. | 6g. Other |
| 22 | PX_1155 | Num | 8 | YNF. | 7. Does the subject have evidence of oral candidiasis? |
| 23 | PX_1160 | Num | 8 | | 8. In the past month, has the child had any symptoms affecting his/her nose, eyes, or sinuses? |
| 24 | PX_1170 | Num | 8 | PX_1170F. | 8a. In general, how would you describe the child's symptoms? |
| 25 | PX_1180 | Num | 8 | PX_1180_1190F. | 9. How frequently has the child used antihistamines and/or decongenstants to treat the nose, eye, and sinus symptoms (prescription or over the counter)? |
| 26 | PX_1190 | Num | 8 | PX_1180_1190F. | 10. How frequently has the child used nasal steroids to treat the nose, eye, and sinus symptoms? |
| 27 | PX_1200 | Num | 8 | | 11. MALE TANNER STAGING - Genital stage (range 1-5) |
| 28 | PX_1210 | Num | 8 | | 12. MALE TANNER STAGING - Testicular volume (smallest of right and left) (cc) |
| 29 | PX_1220 | Num | 8 | | 13. MALE TANNER STAGING - Pubic hair stage (range 1-5) |
| 30 | PX_1230 | Num | 8 | | 14. FEMALE TANNER STAGING - Breast stage (range 1-5) |
| 31 | PX_1240 | Num | 8 | | 15. FEMALE TANNER STAGING - Pubic hair stage (range 1-5) |
| 32 | PX_1250 | Num | 8 | YNF. | 16. FEMALE TANNER STAGING - Has menarche occurred? |
| 33 | PX_1260 | Num | 8 | | 17. FEMALE TANNER STAGING - What was the child's age at menarche? |
| 34 | PX_1270 | Num | 8 | | Flag: Physician/CC signature |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|--|
| 35 | PX_1280 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) |

Data Set Name: priormed.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | PRM_1000 | Num | 8 | YNF. | 2. In the past 12 months, has the participant used any asthma medication(s) other than albuterol (Proventil, Ventolin)? |
| 5 | PRM_1010 | Num | 8 | | 3a. In the past 12 months, for how many months has the participant used the following medications: Salmeterol (Serevent) or formoterol (Foradil) |
| 6 | PRM_1020 | Num | 8 | | 3b. In the past 12 months, for how many months has the participant used the following medications: Inhaled or nebulized corticosteroids [beclomethasone (Beclovent, Vanceril, QVAR), budesonide (Pulmicort), flunisolide (Aerobid), etc.] |
| 7 | PRM_1030 | Num | 8 | | 3c. In the past 12 months, for how many months has the participant used the following medications: Montelukast (Singulair) |
| 8 | PRM_1040 | Num | 8 | | 3d. In the past 12 months, for how many months has the participant used the following medications: Zafirlukast (Accolate) |
| 9 | PRM_1050 | Num | 8 | | 3e. In the past 12 months, for how many months has the participant used the following medications: Theophylline (Slo-bid, Theo-dur, Slo-Phyllin) |
| 10 | PRM_1060 | Num | 8 | | 3f. In the past 12 months, for how many months has the participant used the following medications: Advair |
| 11 | PRM_1065 | Num | 8 | | 3g. In the past 12 months, for how many months has the participant used the following medications: Cromolyn/Nedocromil |
| 12 | PRM_1070 | Num | 8 | | 3h. In the past 12 months, for how many months has the participant used the following medications: Other |
| 13 | PRM_1080 | Num | 8 | | 3i. In the past 12 months, for how many months has the participant used the following medications: Other |
| 14 | PRM_1090 | Num | 8 | PRM_1090F. | 4. In the past 12 months, how many courses of prednisolone (Prelone) or prednisone has the participant taken? |
| 15 | PRM_1100 | Num | 8 | PRM_1100F. | 1. Who is the respondent? |

Data Set Name: serious.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | SER_1000 | Num | 8 | | 1. Date of Adverse Event (number of days since enrollment date) |
| 5 | SER_1010 | Char | 6 | | 2. Description of Adverse Event (ICD9 Code) |
| 6 | SER_1020 | Num | 8 | | 3. Time interval between the last administration of the study drug and the Adverse Event. |
| 7 | SER_1030 | Num | 8 | SER_1030F. | 4. What was the unit of time for the above interval? |
| 8 | SER_1040 | Num | 8 | YNF. | 5a. Why was the event serious? - Fatal event |
| 9 | SER_1050 | Num | 8 | YNF. | 5b. Why was the event serious? - Life-threatening event |
| 10 | SER_1060 | Num | 8 | YNF. | 5c. Why was the event serious? - Inpatient hospitalization required |
| 11 | SER_1070 | Num | 8 | | 5c1. Admission date (number of days since enrollment date) |
| 12 | SER_1080 | Num | 8 | | 5c2. Discharge date (number of days since enrollment date) |
| 13 | SER_1090 | Num | 8 | YNF. | 5d. Why was the event serious? - Hospitalization prolonged |
| 14 | SER_1100 | Num | 8 | YNF. | 5e. Why was the event serious? - Disabling or incapacitating |
| 15 | SER_1110 | Num | 8 | YNF. | 5f. Why was the event serious? - Overdose |
| 16 | SER_1120 | Num | 8 | YNF. | 5g. Why was the event serious? - Cancer |
| 17 | SER_1130 | Num | 8 | YNF. | 5h. Why was the event serious? - Congenital anomaly |
| 18 | SER_1140 | Num | 8 | YNF. | 5i. Why was the event serious? - Serious laboratory abnormality with clinical symptoms |
| 19 | SER_1145 | Num | 8 | YNF. | 5j. Why was the event serious? - Height failure |
| 20 | SER_1150 | Num | 8 | YNF. | 51. Why was the event serious? - Other |
| 21 | SER_1147 | Num | 8 | YNNAF. | 5k. Why was the event serious? - Pregnancy |
| 22 | SER_1160 | Num | 8 | YNF. | 6a. What, in your opinion, caused the event? - Toxicity of study drug(s) |
| 23 | SER_1170 | Num | 8 | YNF. | 6b. What, in your opinion, caused the event? - Withdrawal of study drug(s) |
| 24 | SER_1180 | Num | 8 | YNF. | 6c. What, in your opinion, caused the event? - Concurrent medication |
| 25 | SER_1190 | Num | 8 | YNF. | 6d. What, in your opinion, caused the event? - Concurrent disorder |
| 26 | SER_1200 | Num | 8 | YNF. | 6e. What, in your opinion, caused the event? - Other event |

Data Set Name: sexam.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|----------------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | SX_1000 | Num | 8 | YNF. | 1. Was the Harpenden stadiometer calibrated, per CARE MOP, immediately prior to the visit? |
| 5 | SX_1010 | Num | 8 | | 2. Time measurements started (based on 24-hour clock) |
| 6 | SX_1020 | Num | 8 | | 3a. Standing height (barefoot or thin socks) - First measurement (cm) |
| 7 | SX_1030 | Num | 8 | | 3b. Standing height (barefoot or thin socks) - Second measurement (cm) |
| 8 | SX_1040 | Num | 8 | | 3c. Standing height (barefoot or thin socks) - Third measurement (cm) |
| 9 | SX_1041 | Num | 8 | | 3d. Standing height (barefoot or thin socks) - Average height measurement (cm) |
| 10 | SX_1045 | Num | 8 | YNF. | 3e. In your judgement, was the subject's height measurement acceptable? |
| 11 | SX_1050 | Num | 8 | | 4. Weight (shoes off, light clothing) (kg) |
| 12 | SX_1060 | Num | 8 | YNF. | 5. Is chest auscultation clear? |
| 13 | SX_1070 | Num | 8 | YNF. | 5a. Slight expiratory wheeze |
| 14 | SX_1080 | Num | 8 | YNF. | 5b. Loud expiratory wheeze |
| 15 | SX_1090 | Num | 8 | YNF. | 5c. Inspiratory and expiratory wheezes |
| 16 | SX_1100 | Num | 8 | YNF. | 5d. Acute respiratory distress |
| 17 | SX_1110 | Num | 8 | YNF. | 5e. Rales and/or rhonchi |
| 18 | SX_1120 | Num | 8 | YNF. | 5f. Crackles |
| 19 | SX_1130 | Num | 8 | YNF. | 5g. Other |
| 20 | SX_1135 | Num | 8 | YNF. | 6. Does the subject have evidence of oral candidiasis? |
| 21 | SX_1140 | Num | 8 | YNF. | 7. Does the child currently have any symptoms that affect his/her nose, eyes, or sinuses? |
| 22 | SX_1150 | Num | 8 | SX_1150_1260F. | 8. In general, how would you describe the child's symptoms? |
| 23 | SX_1160 | Num | 8 | SX_1160_1170F. | 9. Since the last clinic visit, how frequently has the child used antihistamines and/or decongestancts to treat nose, eye, and sinus symptoms (prescription or over the counter)? |
| 24 | SX_1170 | Num | 8 | SX_1160_1170F. | 10. Since the last clinic visit, how frequently has the child used nasal steroids to treat nose, eye, and sinus symptoms? |
| 25 | SX_1180 | Num | 8 | | 11. Since the last clinic visit, how many times have you contacted or visited a doctor because of problems with tthe child's nose, eyes, or sinuses? |
| 26 | SX_1190 | Num | 8 | | 12. Since the last clinic visit, how many times has the child had a sinus infection that required treatment with antibiotics? |
| 27 | SX_1200 | Num | 8 | | 13. Since the last clinic visit, how many times has the child had a sinus infection that required treatment with an oral steroid? |
| 28 | SX_1210 | Num | 8 | YNF. | 14. Does the child currently have any eczema? |
| 29 | SX_1220 | Num | 8 | YNF. | 15a. Which parts of the child's body are affected by eczema? Head |
| 30 | SX_1230 | Num | 8 | YNF. | 15b. Which parts of the child's body are affected by eczema? Arms/Hands |
| 31 | SX_1240 | Num | 8 | YNF. | 15c. Which parts of the child's body are affected by eczema? Trunk (mid-section or torso) |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|----------------|---|
| 32 | SX_1250 | Num | 8 | YNF. | 15d. Which parts of the child's body are affected by eczema? Legs/Feet |
| 33 | SX_1255 | Num | 8 | YNF. | 15e. Which parts of the child's body are affected by eczema? Other |
| 34 | SX_1260 | Num | 8 | SX_1150_1260F. | 16. In general, how would you describe the child's eczema? |
| 35 | SX_1270 | Num | 8 | | Flag: Physician/CC signature |
| 36 | SX_1280 | Num | 8 | | Physician/CC signature Date (number of days since enrollment date) |
| 37 | SX_1300 | Num | 8 | YNF. | Ask the respondent: Has the child experienced any new medical conditions since the last clinic visit? |

Data Set Name: skin.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | SKN_2000 | Num | 8 | YNF. | 1. Has the subject had a previous skin test using CARE procedures within the approved time limit? |
| 5 | SKN_2010 | Num | 8 | | 1. Date of previous skin test (number of days since enrollment date) |
| 6 | SKN_1000 | Num | 8 | YNF. | 2. Has the child used any of the medications, listed in the skin test section of the CARE MOP, within the exclusionary periods? |
| 7 | SKN_1010 | Num | 8 | YNF. | 3. Has the child ever had a severe systemic reaction to allergy skin testing? |
| 8 | SKN_1020 | Num | 8 | YNF. | 4. Has the child ever had an anaphylactic reaction to egg? |
| 9 | SKN_1030 | Num | 8 | YNF. | 5. Has the child ever had an anaphylactic reaction to peanut? |
| 10 | SKN_1040 | Num | 8 | YNF. | 6. Has the child ever had an anaphylactic reaction to milk? |
| 11 | SKN_1050 | Num | 8 | | Time test sites pricked (based on 24-hour clock) |
| 12 | SKN_1060 | Num | 8 | | Time test sites evaluated (based on 24-hour clock) |
| 13 | SKN_1070 | Num | 8 | YNF. | 8. Saline (A8) - Was there a reaction? |
| 14 | SKN_1080 | Num | 8 | | 8. Saline (A8) - Largest Wheal Diameter (mm) |
| 15 | SKN_1090 | Num | 8 | | 8. Saline (A8) - Perpindicular Wheal Diameter (mm) |
| 16 | SKN_1100 | Num | 8 | YNF. | 2. Mite Mix (A2) - Was there a reaction? |
| 17 | SKN_1110 | Num | 8 | | 2. Mite Mix (A2) - Largest Wheal Diameter (mm) |
| 18 | SKN_1120 | Num | 8 | | 2. Mite Mix (A2) - Perpindicular Wheal Diameter (mm) |
| 19 | SKN_1130 | Num | 8 | YNF. | 3. Roach Mix (A3) - Was there a reaction? |
| 20 | SKN_1140 | Num | 8 | | 3. Roach Mix (A3) - Largest Wheal Diameter (mm) |
| 21 | SKN_1150 | Num | 8 | | 3. Roach Mix (A3) - Perpindicular Wheal Diameter (mm) |
| 22 | SKN_1160 | Num | 8 | YNF. | 4. Cat (A4) - Was there a reaction? |
| 23 | SKN_1170 | Num | 8 | | 4. Cat (A4) - Largest Wheal Diameter (mm) |
| 24 | SKN_1180 | Num | 8 | | 4. Cat (A4) - Perpindicular Wheal Diameter (mm) |
| 25 | SKN_1190 | Num | 8 | YNF. | 5. Dog (A5) - Was there a reaction? |
| 26 | SKN_1200 | Num | 8 | | 5. Dog (A5) - Largest Wheal Diameter (mm) |
| 27 | SKN_1210 | Num | 8 | | 5. Dog (A5) - Perpindicular Wheal Diameter (mm) |
| 28 | SKN_1220 | Num | 8 | YNF. | 6. Mold Mix (A6) - Was there a reaction? |
| 29 | SKN_1230 | Num | 8 | | 6. Mold Mix (A6) - Largest Wheal Diameter (mm) |
| 30 | SKN_1240 | Num | 8 | | 6. Mold Mix (A6) - Perpindicular Wheal Diameter (mm) |
| 31 | SKN_1250 | Num | 8 | YNF. | 7. Grass Mix (A7) - Was there a reaction? |
| 32 | SKN_1260 | Num | 8 | | 7. Grass Mix (A7) - Largest Wheal Diameter (mm) |
| 33 | SKN_1270 | Num | 8 | | 7. Grass Mix (A7) - Perpindicular Wheal Diameter (mm) |
| 34 | SKN_1280 | Num | 8 | YNF. | 9. Tree Mix (B1) - Was there a reaction? |
| 35 | SKN_1290 | Num | 8 | | 9. Tree Mix (B1) - Largest Wheal Diameter (mm) |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 36 | SKN_1300 | Num | 8 | | 9. Tree Mix (B1) - Perpindicular Wheal Diameter (mm) |
| 37 | SKN_1310 | Num | 8 | YNF. | 10. Weed Mix (B2) - Was there a reaction? |
| 38 | SKN_1320 | Num | 8 | | 10. Weed Mix (B2) - Largest Wheal Diameter (mm) |
| 39 | SKN_1330 | Num | 8 | | 10. Weed Mix (B2) - Perpindicular Wheal Diameter (mm) |
| 40 | SKN_1340 | Num | 8 | YNF. | 11. Milk (B3) - Was there a reaction? |
| 41 | SKN_1350 | Num | 8 | | 11. Milk (B3) - Largest Wheal Diameter (mm) |
| 42 | SKN_1360 | Num | 8 | | 11. Milk (B3) - Perpindicular Wheal Diameter (mm) |
| 43 | SKN_1370 | Num | 8 | YNF. | 12. Egg (B4) - Was there a reaction? |
| 44 | SKN_1380 | Num | 8 | | 12. Egg (B4) - Largest Wheal Diameter (mm) |
| 45 | SKN_1390 | Num | 8 | | 12. Egg (B4) - Perpindicular Wheal Diameter (mm) |
| 46 | SKN_1400 | Num | 8 | YNF. | 13. Peanut (B5) - Was there a reaction? |
| 47 | SKN_1410 | Num | 8 | | 13. Peanut (B5) - Largest Wheal Diameter (mm) |
| 48 | SKN_1420 | Num | 8 | | 13. Peanut (B5) - Perpindicular Wheal Diameter (mm) |
| 49 | SKN_1430 | Num | 8 | YNF. | 15. Other (B7) - Was there a reaction? |
| 50 | SKN_1440 | Num | 8 | | 15. Other (B7) - Largest Wheal Diameter (mm) |
| 51 | SKN_1450 | Num | 8 | | 15. Other (B7) - Perpindicular Wheal Diameter (mm) |
| 52 | SKN_1460 | Num | 8 | YNF. | 14. Other (B6) - Was there a reaction? |
| 53 | SKN_1470 | Num | 8 | | 14. Other (B6) - Largest Wheal Diameter (mm) |
| 54 | SKN_1480 | Num | 8 | | 14. Other (B6) - Perpindicular Wheal Diameter (mm) |
| 55 | SKN_1490 | Num | 8 | YNF. | 1. Histamine (A1) - Was there a reaction? |
| 56 | SKN_1500 | Num | 8 | | 1. Histamine (A1) - Largest Wheal Diameter (mm) |
| 57 | SKN_1510 | Num | 8 | | 1. Histamine (A1) - Perpindicular Wheal Diameter (mm) |
| 58 | SKN_1520 | Num | 8 | YNF. | 16. Other (B8) - Was there a reaction? |
| 59 | SKN_1530 | Num | 8 | | 16. Other (B8) - Largest Wheal Diameter (mm) |
| 60 | SKN_1540 | Num | 8 | | 16. Other (B8) - Perpindicular Wheal Diameter (mm) |

Data Set Name: spiro.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | SPR_1000 | Num | 8 | YNF. | 1. During the past 24 hours, has the participant used sustained-release theophylline? |
| 5 | SPR_1010 | Num | 8 | YNF. | 2. During the past 12 hours, has the participant used a long-acting bronchodilator (i.e., salmeterol)? |
| 6 | SPR_1020 | Num | 8 | YNF. | 3. During the past 4 hours, has the participant used a short-acting bronchdilator? |
| 7 | SPR_1030 | Num | 8 | YNF. | 4. During the past 2 weeks, has the participant had any respiratory infections, colds, or bronchitis? |
| 8 | SPR_1035 | Num | 8 | YNF. | 5. Is there any other reason the participant should not proceed with the pulmonary function testing? |
| 9 | SPR_1040 | Num | 8 | YNF. | 6. Is the participant eligible to preed with the pulmonary function testing? |
| 10 | SPR_1055 | Num | 8 | YNF. | 8. Did the participant refuse to perform the procedure? |
| 11 | SPR_1060 | Num | 8 | | 9. Time spirometry started (based on 24-hour clock) |
| 12 | SPR_1080 | Num | 8 | | 10a. Results of best effort - FVC |
| 13 | SPR_1090 | Num | 8 | | 10b. Results of best effort - FEV1 |
| 14 | SPR_1100 | Num | 8 | | 10c. Results of best effort - FEV1 (% predicted) |
| 15 | SPR_1110 | Num | 8 | | 10d. Results of best effort - FEV1/FVC |
| 16 | SPR_1120 | Num | 8 | | 10e. Results of best effort - FEF25-75 |
| 17 | SPR_1130 | Num | 8 | | 10f. Results of best effort - FEF50 |
| 18 | SPR_1140 | Num | 8 | | 10g. Results of best effort - FEF75 |
| 19 | SPR_1150 | Num | 8 | | 10h. Results of best effort - PEF (best effort) |
| 20 | SPR_1151 | Num | 8 | | 10i. Results of best effort - FET |
| 21 | SPR_1152 | Num | 8 | | 10j. Results of best effort - FET PEF |
| 22 | SPR_1153 | Num | 8 | | 10k. Results of best effort - V backextrapolation ex |
| 23 | SPR_1154 | Num | 8 | | 10l. Results of best effort - V backextrapolation % FVC |
| 24 | SPR_1155 | Num | 8 | | 10m. Results of best effort - ATS Accepted |
| 25 | SPR_1156 | Num | 8 | | 10n. Results of best effort - ATS Error Code |
| 26 | SPR_1290 | Num | 8 | YNF. | 11. In your judgement, was the participant's prebronchodilator technique acceptable? |
| 27 | SPR_1300 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Inadequate inspiratory effort |
| 28 | SPR_1310 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Inadequate expiratory effort |
| 29 | SPR_1320 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Inadequate duration of expiration |
| 30 | SPR_1330 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Cough during procedure |
| 31 | SPR_1335 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Participant refusal during test |
| 32 | SPR_1340 | Num | 8 | YNF. | 11a. If NO, why was it unacceptable? Other |
| 33 | SPR_1350 | Num | 8 | SPR_1350_1280F. | 11b. If YES, grade the participant's technique. |
| 34 | SPR_1260 | Num | 8 | YNF. | 15. In your judgement, was the participant's postbronchodilator technique acceptable? |

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|-----------------|---|
| 35 | SPR_1170 | Num | 8 | | 13. Time postbronchodilator spirometry started (based on 24-hour clock) |
| 36 | SPR_1180 | Num | 8 | | 14a. Results of best effort - FVC |
| 37 | SPR_1190 | Num | 8 | | 14b. Results of best effort - FEV1 |
| 38 | SPR_1200 | Num | 8 | | 14c. Results of best effort - FEV1 (% predicted) |
| 39 | SPR_1210 | Num | 8 | | 14d. Results of best effort - FEV1/FVC |
| 40 | SPR_1220 | Num | 8 | | 14e. Results of best effort - FEF25-75 |
| 41 | SPR_1230 | Num | 8 | | 14f. Results of best effort - FEF50 |
| 42 | SPR_1240 | Num | 8 | | 14g. Results of best effort - FEF75 |
| 43 | SPR_1250 | Num | 8 | | 14h. Results of best effort - PEF (best effort) |
| 44 | SPR_1251 | Num | 8 | | 14i. Results of best effort - FET |
| 45 | SPR_1252 | Num | 8 | | 14j. Results of best effort - FET PEF |
| 46 | SPR_1253 | Num | 8 | | 14k. Results of best effort - V backextrapolation ex |
| 47 | SPR_1254 | Num | 8 | | 14l. Results of best effort - V backextrapolation % FVC |
| 48 | SPR_1255 | Num | 8 | | 14m. Results of best effort - ATS Accepted |
| 49 | SPR_1256 | Num | 8 | | 14n. Results of best effort - ATS Error Code |
| 50 | SPR_1270 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Inadequate inspiratory effort |
| 51 | SPR_1271 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Inadequate expiratory effort |
| 52 | SPR_1272 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Inadequate duration of expiration |
| 53 | SPR_1273 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Cough during procedure |
| 54 | SPR_1275 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Participant refusal during test |
| 55 | SPR_1274 | Num | 8 | YNF. | 15a. If NO, why was it unacceptable? Other |
| 56 | SPR_1280 | Num | 8 | SPR_1350_1280F. | 15b. If YES, grade the participant's technique. |

Data Set Name: term.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|------------|--|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | TRM_1010 | Num | 8 | YNF. | 1. Has the participant completed the study? |
| 5 | TRM_1020 | Num | 8 | YNF. | 2. Has the participant been deemed ineligible during the assessment/characterization period? |
| 6 | TRM_1030 | Num | 8 | YNNAF. | 3. Has the participant been withdrawn from the study due to pregnanacy? |
| 7 | TRM_1050 | Num | 8 | | Participant's Initials Date (number of days since enrollment date) |
| 8 | TRM_1060 | Num | 8 | YNF. | 4. Has the participant been assigned treatment failure status? |
| 9 | TRM_1070 | Num | 8 | YNF. | 5. Is there any other reason why the participant is being terminated from the study? |
| 10 | TRM_1080 | Num | 8 | TRM_1080F. | 5. If YES, indicate the primary reason. |
| 11 | TRM_1090 | Num | 8 | YNF. | 6. Has the participant been lost to follow up? |
| 12 | TRM_1100 | Num | 8 | YNF. | 7. Has the participant experienced a serious adverse event (i.e., an adverse event resulting in death or hospitalization, etc.)? |
| 13 | TRM_1110 | Num | 8 | YNF. | 8. Did a physician initiate the termination of study participation? |
| 14 | TRM_1120 | Num | 8 | | Flag: Clinic Coordinator's Signature |
| 15 | TRM_1130 | Num | 8 | | Date of Clinic Coordinator's Signature (number of days since enrollment date) |
| 16 | TRM_1140 | Num | 8 | | Flag: Principal Investigator's Signature |
| 17 | TRM_1150 | Num | 8 | | Date of Principal Investigator's Signature (number of days since enrollment date) |

Data Set Name: trtfail.sas7bdat

| Num | Variable | Type | Len | Format | Label |
|-----|----------|------|-----|--------|---|
| 1 | SUBJ_ID | Num | 8 | | Public Subject ID |
| 2 | VNUM | Num | 8 | | Visit Number |
| 3 | VDATE | Num | 8 | | Visit Date (number of days since enrollment date) |
| 4 | TXF_1000 | Num | 8 | YNF. | 1. Has the participant required emergency department treatment for asthma? |
| 5 | TXF_1010 | Num | 8 | YNF. | 2. Has the participant been hospitalized for asthma? |
| 6 | TXF_1020 | Num | 8 | YNF. | 3. Has the participant had a hypoxic seizure due to asthma? |
| 7 | TXF_1030 | Num | 8 | YNF. | 4. Has the participant required intubation for asthma? |
| 8 | TXF_1040 | Num | 8 | YNF. | 5a. Has the participant received any of the following non-study medications? Systemic (oral, IV, IM, SC) corticosteroids |
| 9 | TXF_1050 | Num | 8 | YNF. | 5b. Has the participant received any of the following non-study medications? Inhaled oral corticosteroids |
| 10 | TXF_1060 | Num | 8 | YNF. | 5c. Has the participant received any of the following non-study medications? Salmetrerol |
| 11 | TXF_1070 | Num | 8 | YNF. | 5d. Has the participant received any of the following non-study medications? Theophylline |
| 12 | TXF_1080 | Num | 8 | YNF. | 5e. Has the participant received any of the following non-study medications? Leukotriene modifier (Accolate (zafirlukast), Singulair (montelukast), Zileutin (zyflo)) |
| 13 | TXF_1090 | Num | 8 | YNF. | 6. Is the participant a treatment failure? |
| 14 | TXF_1100 | Num | 8 | | 7. Date treatment failure occurred (number of days since enrollment date) |
| 15 | TXF_1110 | Num | 8 | | Flag: Physician/CC signature |
| 16 | TXF_1120 | Num | 8 | | Date of Physician/CC signature (number of days since enrollment date) |